{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/33555"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/33555","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"The potential commercialization of neuronal replacement therapy using smart polymers","abstract":"NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.","abstract_html":"NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.","abstract_has_math":false,"creators":["Dutt, Anindita, 1971-"],"institution":"Massachusetts Institute of Technology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Management of Technology Program.","school":null,"contributors":[],"advisors":["Edward B. Roberts, Robert S. Langer and Mriganka Sur."],"committee_chairs":[],"committee_members":[],"year":2005,"date_issued":"2005","date_published":"2005","updated_at":"2026-07-22T22:21:26Z","subjects":["Management of Technology Program."],"languages":["eng"],"rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"rights_urls":["http://dspace.mit.edu/handle/1721.1/7582"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1721.1/33555","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Edward B. Roberts, Robert S. Langer and Mriganka Sur."]},{"key":"dc:contributor.department","label":"Department","values":["Management of Technology Program."]},{"key":"dc:contributor.other","label":"Dc Contributor Other","values":["Management of Technology Program."]},{"key":"dc:creator","label":"Author","values":["Dutt, Anindita, 1971-"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2006-07-31T15:12:12Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2006-07-31T15:12:12Z"]},{"key":"dc:date.issued","label":"Date","values":["2005"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Management of Technology Program."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://dspace.mit.edu/handle/1721.1/7582"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1721.1/33555"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (S.M.M.O.T.)--Massachusetts Institute of Technology, Sloan School of Management, Management of Technology Program, 2005.","Includes bibliographical references (leaves 108-122)."]},{"key":"dc:description.abstract","label":"Abstract","values":["NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["S.M.M.O.T."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The potential commercialization of neuronal replacement therapy using smart polymers"]}]}],"canonical_facts":{"dc:contributor.advisor":["Edward B. Roberts, Robert S. Langer and Mriganka Sur."],"dc:contributor.department":["Management of Technology Program."],"dc:contributor.other":["Management of Technology Program."],"dc:creator":["Dutt, Anindita, 1971-"],"dc:date.accessioned":["2006-07-31T15:12:12Z"],"dc:date.available":["2006-07-31T15:12:12Z"],"dc:date.issued":["2005"],"dc:description":["Thesis (S.M.M.O.T.)--Massachusetts Institute of Technology, Sloan School of Management, Management of Technology Program, 2005.","Includes bibliographical references (leaves 108-122)."],"dc:description.abstract":["NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm."],"dc:description.degree":["S.M.M.O.T."],"dc:format.mimetype":["application/pdf"],"dc:identifier.uri":["http://hdl.handle.net/1721.1/33555"],"dc:language.iso":["eng"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission."],"dc:rights.uri":["http://dspace.mit.edu/handle/1721.1/7582"],"dc:subject":["Management of Technology Program."],"dc:title":["The potential commercialization of neuronal replacement therapy using smart polymers"],"dc:type":["Thesis"]},"updated_at":"2026-07-22T22:21:26Z"}